Heparin-induced thrombocytopenia and cardiac surgery

Annals of Thoracic Surgery

Volumn 76, Issue 2, 2003, Pages 638-648

  Warkentin, Theodore E ^a   Greinacher, Andreas ^b  

^a HAMILTON HEALTH SCIENCES   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; DANAPAROID; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; ILOPROST; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PROSTACYCLIN; THROMBOCYTE ANTIBODY; TIROFIBAN; WARFARIN;

ANAPHYLAXIS; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; HEART SURGERY; HUMAN; HYPOTENSION; IMMUNOGENICITY; LIMB DISEASE; NECROSIS; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; TREATMENT OUTCOME; VEIN THROMBOSIS;

EID: 0037610516     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(03)00756-2     Document Type: Review

References (72)

1. Warkentin TE. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Recommendations of the College of American Pathologists. Arch Pathol Lab Med 2002;126:1415-23.
2. Warkentin TE. Heparin-induced thrombocytopenia and the anesthesiologist. Can J Anesth 2002;49(Suppl):S36-49.
3. Greinacher A, Lubenow N. Recombinant hirudin in clinical practice: focus on lepirudin. Circulation 2001;103:1479-84.
4. McKeage K, Plosker GL. Argatroban. Drugs 2001;61:515-22.
5. Ibbotson T, Perry CM. Danaparoid: a review of its use in thromboembolic and coagulation disorders. Drugs 2002;62:2283-314.
6. Sciulli TM, Mauro VF. Pharmacology and clinical use of bivalirudin. Ann Pharmacother 2002;36:1028-41.
7. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 1998;79:1-7.
8. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003; in press.
9. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5.
10. Pouplard C, May MA, Iochmann S, et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation 1999;99:2530-6.
11. Pouplard C, May MA, Regina S, Maakaroun A, Fusciardi J, Gruel Y. Changes in the platelet count after cardiopulmonary bypass can efficiently predict the development of pathogenic heparin-dependent antibodies [Abstract]. Blood 2002;100:16a-7a.
12. Lee DH, Warkentin TE. Frequency of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced thrombocytopenia, 2nd ed. New York: Marcel Dekker, 2001:87-121.
13. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996;101:502-7.
14. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001;344:1286-92.
15. Lubenow N, Kempf R, Eichner A, Eichler P, Carlsson LE, Greinacher A. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest 2002;122:37-42.
16. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001;135:502-6.
17. Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced thrombocytopenia, 2nd ed. New York: Marcel Dekker, 2001:43-86.
18. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003.
19. Martin JF, Daniel TD, Trowbridge EA. Acute and chronic changes in platelet volume and count after cardiopulmonary bypass induced thrombocytopenia in man. Thromb Haemost 1987;57:55-8.
20. Hong AP, Cook DJ, Sigouin CS, Warkentin TE. Central venous catheters and upper-extremity deep-vein thrombosis complicating heparin-induced thrombocytopenia. Blood 2003; in press.
21. Walls JT, Curtis JJ, Silver D, Boley TM, Schmaltz RA, Nawarawong W. Heparin-induced thrombocytopenia in open heart surgical patients: sequelae of late recognition. Ann Thorac Surg 1992;53:787-91.
22. Walls JT, Boley TM, Curtis JJ, Silver D. Heparin-induced thrombocytopenia in patients undergoing intra-aortic balloon pumping after open heart surgery. ASAIO J 1992;38:M574-6.
23. Glock Y, Szmil E, Boudjema B, et al. Cardiovascular surgery and heparin-induced thrombocytopenia. Int Angiol 1988;7:238-45.
24. Singer RL, Mannion JD, Bauer TL, Armenti FR, Edie RN. Complications from heparin-induced thrombocytopenia in patients undergoing cardiopulmonary bypass. Chest 1993;104:1436-40.
25. Liu JC, Lewis BE, Steen LH, et al. Patency of coronary artery bypass grafts in patients with heparin-induced thrombocytopenia. Am J Cardiol 2002;89:979-81.
26. Aird WC, Mark EJ. A 53-year-old man with a myocardial infarct and thromboses after coronary-artery bypass grafting. N Engl J Med 2002;346:1562-70.
27. Lubenow N, Eichler P, Albrecht D, et al. Very low platelet counts in post-transfusion purpura falsely diagnosed as heparin-induced thrombocytopenia. Report of four cases and review of literature. Thromb Res 2000;100:115-25.
28. Warkentin TE, Sheppard JI, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000;96:1703-8.
29. Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep 2003;2:148 -57.
30. Trossaërt M, Gaillard A, Commin PL, Amiral J, Vissac AM, Fressinaud E. High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery. Br J Haematol 1998;101:653-5.
31. Bauer TL, Arepally G, Konkle BA, et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 1997;95:1242-6.
32. Konkle BA, Bauer TL, Arepally G, et al. Heparin-induced thrombocytopenia: bovine versus porcine heparin in cardiopulmonary bypass surgery. Ann Thorac Surg 2001;71:1920-4.
33. Francis JL, Palmer GP III, Moroose R, Drexler A. Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery. Ann Thorac Surg 2003;75:17-22.
34. Warkentin TE. Pork or beef? Ann Thorac Surg 2003;75:17-22.
35. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119(Suppl):64S-94.
36. Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. J Thromb Hemost 2003; in press.
37. Warkentin TE, Elavathil LJ, Hayward CPM, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997;127:804-12.
38. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of two prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000;96:846-51.
39. Pötzsch B, Klövekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia [Letter]. N Engl J Med 2000;343:515.
40. Selleng S, Lubenow N, Wollert HG, Mullejans B, Greinacher A. Emergency cardiopulmonary bypass in a bilaterally nephrectomized patient with a history of heparin-induced thrombocytopenia: successful reexposure to heparin. Ann Thorac Surg 2001;71:1041-2.
41. Olinger GN, Hussey CV, Olive JA, Malik MI. Cardiopulmonary bypass for patients with previously documented heparin-induced platelet aggregation. J Thorac Cardiovasc Surg 1984;87:673-7.
42. Poetzsch B, Madlener K. Management of cardiopulmonary bypass anticoagulation in patients with heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced thrombocytopenia, 2nd ed. New York: Marcel Dekker, 2001:429-44.
43. Lewis BE, Matthai WH Jr, Cohen M, Moses JW, Hursting MJ, Leya F. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv 2002;57:177-84.
44. Campbell KR, Mahaffey KW, Lewis BE, et al. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. J Invasive Cardiol 2000;12(Suppl F):14F-9.
45. Chong BH, Magnani HN. Danaparoid for the treatment of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced thrombocytopenia, 2nd ed. New York: Marcel Dekker, 2001:323-47.
46. Palmer Smith J, Walls JT, Muscato MS, et al. Extracorporeal circulation in a patient with heparin-induced thrombocytopenia. Anesthesiology 1985;62:363-5.
47. Olbricht K, Wiersbitzky M, Wacke W, et al. Atypical heparin-induced thrombocytopenia complicated by intracardiac thrombus effectively treated with ultra-low-dose rt-PA lysis and recombinant hirudin (lepirudin). Blood Coagul Fibrinolysis 1998;9:273-7.
48. Warkentin TE, Dunn GL, Cybulsky IJ. Off-pump coronary artery bypass grafting for acute heparin-induced thrombocytopenia. Ann Thorac Surg 2001;72:1730-2.
49. Koster A, Kuppe H, Crystal GJ, Mertzlufft F. Cardiovascular surgery without cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II using anticoagulation with recombinant hirudin. Anesth Analg 2000;90:292-8.
50. Spiess BD, DeAnda A, McCarthy A, Yeatman D, Harness HL, Katlaps G. Off pump CABG in a patient with HITT anticoagulated with bivalirudin: a case report [Abstract]. Anesth Analg 2002;93:SCA70.
51. Merry AF, Raudkivi P, White HD, et al. Anticoagulation with bivalirudin (a direct thrombin inhibitor) vs heparin. A randomized trial in OPCAB graft surgery [Abstract]. Anesth Analg 2002;93:SCA33.
52. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. REPLACE-2 randomized trial. JAMA 2003;289:853-63.
53. Despotis GJ, Hogue CW, Saleem R, et al. The relationship between hirudin and activated clotting time: implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery. Anesth Analg 2001;93:28-32.
54. Pötzsch B, Madlener K, Seelig C, Riess CF, Greinacher A, Müller-Berghaus G. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass - assessment of the whole blood ecarin clotting time. Thromb Haemost 1997;77:920-5.
55. Lindhoff-Last E, Piechottka GP, Rabe F, Bauersachs R. Hirudin determination in plasma can be strongly influenced by the prothrombin level. Thromb Res 2000;100:55-60.
56. Koster A, Loebe M, Hansen R, et al. A quick assay for monitoring recombinant hirudin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: adaptation of the ecarin clotting time to the act II device. J Thorac Cardiovasc Surg 2000;119:1278-83.
57. Koster A, Hansen R, Grauhan O, et al. Hirudin monitoring using the TAS ecarin clotting time in patients with heparin-induced thrombocytopenia type II. J Cardiothorac Vasc Anesth 2000;14:249-52.
58. Riess FC, Löwer C, Seelig C, et al. Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: successful for aortic valve replacement in man. Thorac Cardiovasc Surg 1995;110:265-7.
59. Riess FC, Pötzsch B, Bader K, et al. A case report on the use of recombinant hirudin as an anticoagulant for cardiopulmonary bypass in open heart surgery. Eur J Cardiothorac Surg 1996;10:386-8.
60. Koster A, Merkle F, Hansen R, et al. Elimination of recombinant hirudin by modified ultrafiltration during simulated cardiopulmonary bypass: assessment of different filter systems. Anesth Analg 2000;91:265-9.
61. Koster A, Chew D, Grundel M, Bauer M, Kuppe H, Spiess BD. Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass. Anesth Analg 2003;96:383-6.
62. Koster A, Chew D, Grundel M, Hausmann H, Kuppe H, Spiess BD. Assessment of different filter systems for extracorporeal elimination of bivalirudin: an in vitro study. Anesth Analg 2003; in press.
63. Vasquez JC, Vichiendilokkul A, Mahmood S, Baciewicz FA Jr. Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery. Ann Thorac Surg 2002;74:2177-9.
64. Davis Z, Anderson R, Short D, Garber D, Valgiusti A. Favorable outcome with bivalirudin anticoagulation during cardiopulmonary bypass. Ann Thorac Surg 2003;75:264-5.
65. Gitlin SD, Deeb GM, Yann C, Schmaier AH. Intraoperative monitoring of danaparoid sodium anticoagulation during cardiovascular operations. J Vasc Surg 1998;27:568-75.
66. Doherty DC, Ortel TL, De Bruijn N, Greenberg CS, Van Trigt PIII. "Heparin-free" cardiopulmonary bypass: first reported use of heparinoid (Org 10172) to provide anticoagulation for cardiopulmonary bypass. Anesthesiology 1990;73:562-5.
67. Magnani HN, Beijering RJR, ten Cate JW, Chong BH. Orgaran anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. In: Pifarre R, ed. New anticoagulants for the cardiovascular patient. Philadelphia: Hanlev & Belfus, 1997:487-500.
68. Addonizio VPJr, Fisher CA, Kappa JR, Ellison N. Prevention of heparin-induced thrombocytopenia during open heart surgery with iloprost (ZK36374). Surgery 1987;102:796-807.
69. Aouifi A, Blanc P, Piriou V, et al. Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia. Ann Thorac Surg 2001;71:678-83.
70. Mertzlufft F, Kuppe H, Koster A. Management of urgent high-risk cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and coexisting disorders of renal function: use of heparin and epoprostenol combined with on-line monitoring of platelet function. J Cardiothorac Vasc Anesth 2000;14:304-8.
71. Koster A, Meyer O, Fischer T, et al. One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban, and heparin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II. J Thorac Cardiovasc Surg 2001;122:1254-5.
72. Kawada T, Kitagawa H, Hoson M, Okada Y, Shiomura J. Clinical application of argatroban as an alternative anticoagulant for extracorporeal circulation. Hematol Oncol Clin N Am 2000;14:445-57.